HCV-related Factors but not HIV-Related Factors at Baseline Predict the Response to Treatment With Peginterferon alfa-2a (40KD) (PEGASYS) Plus Ribavirin (COPEGUS) in Patients With HCV/HIV Co-infection: Predictor Analysis From the APRICOT Study

摘要

In the APRICOT study, the combination of PEGASYS plus COPEGUS produced significantly higher sustained virological response (SVR) rates in patients with HCV/HIV co-infection (40(percent)) than either PEGASYS monotherapy (20(percent)) or the combination of interferon alfa-2b plus ribavirin (12(percent)). We aimed to identify baseline characteristics predictive of an SVR in patients treated with PEGASYS plus COPEGUS.